Shorter blood thinner treatment after heart attack with irregular heartbeat
Part of Heart & circulation clinical trials.
This trial tests whether patients with both irregular heartbeat (atrial fibrillation) and a recent heart attack can safely take a shorter course of blood-thinning medications after a stent procedure. The goal is to reduce bleeding risk while still protecting against future clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old
- You have atrial fibrillation (irregular heartbeat) and a stroke risk score of 2 or higher
- You had a heart attack (either STEMI or NSTEMI type) at least 6 months ago and received a stent
- You can safely take blood thinners like DOACs or clopidogrel without serious side effects
- You do not have severe liver disease, advanced kidney disease, or a history of brain bleeding
- You are not pregnant, planning heart surgery within a year, or unable to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two common blood-thinning medications (prasugrel vs ticagrelor) and two treatment durations (short 1–3 months vs standard 12 months) after a heart attack treated with stents. It aims to find the most effective and safest anti-clotting strategy for patients.
This trial tests whether patients who have had a heart attack or unstable angina and a stent placed with ultrasound guidance can safely stop one of their blood-thinning medicines early. It helps doctors find the best way to prevent future heart problems with fewer side effects.
This trial looks at whether switching to a “lower-intensity” blood thinner plan after a heart attack and stent is safer and still works well. It may help reduce bleeding risk compared with a stronger approach, while protecting the stent from clots.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This study compares different blood-thinner (“antithrombotic”) strategies in people with atrial fibrillation or flutter who recently had a stent placed (PCI). It aims to find a plan that lowers clot risk while keeping bleeding risk as low as possible.
This trial tests whether taking a blood thinner can lower the risk of stroke in people who had atrial fibrillation (an irregular heartbeat) that happened temporarily around a stressful illness or surgery. It looks especially at people at higher risk for stroke after that episode.
Hear when a new ST-segment Elevation Myocardial Infarction (STEMI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.